Cilostazol: a Review of Basic Mechanisms and Clinical Uses

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2021 Apr 16

PMID 33860901

Citations 23

Authors

Riyad Y Kherallah

Muzamil Khawaja

Michael Olson

Dominick Angiolillo

Yochai Birnbaum

Affiliations

Soon will be listed here.

Abstract

Primarily used in the treatment of intermittent claudication, cilostazol is a 2-oxyquinolone derivative that works through the inhibition of phosphodiesterase III and related increases in cyclic adenosine monophosphate (cAMP) levels. However, cilostazol has been implicated in a number of other basic pathways including the inhibition of adenosine reuptake, the inhibition of multidrug resistance protein 4, among others. It has been observed to exhibit antiplatelet, antiproliferative, vasodilatory, and ischemic-reperfusion protective properties. As such, cilostazol has been investigated for clinical use in a variety of settings including intermittent claudication, as an adjunctive for reduction of restenosis after coronary and peripheral endovascular interventions, and in the prevention of secondary stroke, although its widespread implementation for indications other than intermittent claudication has been limited by relatively modest effect sizes and lack of studies in western populations. In this review, we highlight the pleiotropic effects of cilostazol and the evidence for its clinical use.

Citing Articles

Efficacy and safety of using cilostazol versus aspirin in secondary stroke prevention: systematic review and meta-analysis of randomised controlled clinical trials.

Zhuang P, Huang Y, Zheng Z, Zhang X Intern Med J. 2025; 55(3):483-492.

PMID: 40047064 PMC: 11900848. DOI: 10.1111/imj.16657.

The Role of Mitochondrial Quality Control in Liver Diseases: Dawn of a Therapeutic Era.

Li J, Liu W, Zhang J, Sun C Int J Biol Sci. 2025; 21(4):1767-1783.

PMID: 39990657 PMC: 11844277. DOI: 10.7150/ijbs.107777.

Benefits of Cilostazol's Effect on Vascular and Neuropathic Complications Caused by Diabetes.

Musial D, Ajita M, Bomfim G Med Sci (Basel). 2025; 13(1.

PMID: 39846696 PMC: 11755643. DOI: 10.3390/medsci13010001.

Cilostazol geno-protective effects mitigate carbamazepine-induced genotoxicity in human cultured blood lymphocytes.

Al Momany E, Rababah A, Alzoubi K, Khabour O Toxicol Rep. 2024; 13:101814.

PMID: 39654995 PMC: 11626827. DOI: 10.1016/j.toxrep.2024.101814.

The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.

Peng L, Li X, Li J, Liu S, Liang G PLoS One. 2024; 19(12):e0314957.

PMID: 39630707 PMC: 11616863. DOI: 10.1371/journal.pone.0314957.

References

Pearce L, Ghosh J, Counsell A, Serracino-Inglott F . Cilostazol and peripheral arterial disease. Expert Opin Pharmacother. 2008; 9(15):2683-90. DOI: 10.1517/14656566.9.15.2683. View

Noe L, Peeters K, Izzi B, Van Geet C, Freson K . Regulators of platelet cAMP levels: clinical and therapeutic implications. Curr Med Chem. 2010; 17(26):2897-905. DOI: 10.2174/092986710792065018. View

Gerhard-Herman M, Gornik H, Barrett C, Barshes N, Corriere M, Drachman D . 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016; 69(11):1465-1508. DOI: 10.1016/j.jacc.2016.11.008. View

Colman R . Platelet cyclic adenosine monophosphate phosphodiesterases: targets for regulating platelet-related thrombosis. Semin Thromb Hemost. 2004; 30(4):451-60. DOI: 10.1055/s-2004-833480. View

Elam M, HECKMAN J, Crouse J, Hunninghake D, HERD J, Davidson M . Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998; 18(12):1942-7. DOI: 10.1161/01.atv.18.12.1942. View

Chancharoenthana W, Leelahavanichkul A, Taratummarat S, Wongphom J, Tiranathanagul K, Eiam-Ong S . Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease. PLoS One. 2017; 12(12):e0187872. PMC: 5716535. DOI: 10.1371/journal.pone.0187872. View

Lee S, Park S, Kim Y, Yun S, Park D, Lee C . A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II.... J Am Coll Cardiol. 2011; 57(11):1264-70. DOI: 10.1016/j.jacc.2010.10.035. View

DAWSON D, CUTLER B, Hiatt W, Hobson 2nd R, Martin J, Bortey E . A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000; 109(7):523-30. DOI: 10.1016/s0002-9343(00)00569-6. View

Heo S, Lee J, Kim B, Hwang K, Kim J, Chang D . Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients. J Neurol. 2012; 260(1):122-30. PMC: 3535378. DOI: 10.1007/s00415-012-6599-y. View

10.

Planchon S . Abrogating the induction of type 2 diabetes mellitus secondary to statin therapy. Cardiovasc Drugs Ther. 2014; 28(5):393-4. DOI: 10.1007/s10557-014-6551-8. View

11.

Kim J, Kwon S, Uchiyama S . Cilostazol research in Asia: can it be applied to European and American patients?. Int J Stroke. 2015; 10 Suppl 1:1-9. DOI: 10.1111/ijs.12460. View

12.

Gresele P, Momi S, Falcinelli E . Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011; 72(4):634-46. PMC: 3195739. DOI: 10.1111/j.1365-2125.2011.04034.x. View

13.

Liu Y, Cone J, Le S, Fong M, Tao L, Shoaf S . Cilostazol and dipyridamole synergistically inhibit human platelet aggregation. J Cardiovasc Pharmacol. 2004; 44(2):266-73. DOI: 10.1097/00005344-200408000-00017. View

14.

Yun S, Sim E, Goh R, Park J, Han J . Platelet Activation: The Mechanisms and Potential Biomarkers. Biomed Res Int. 2016; 2016:9060143. PMC: 4925965. DOI: 10.1155/2016/9060143. View

15.

Paul S, Feoktistov I, Hollister A, Robertson D, Biaggioni I . Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: evidence that both effects are coupled to adenylate cyclase. Mol Pharmacol. 1990; 37(6):870-5. View

16.

Sudo T, Ito H, Kimura Y . Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. Platelets. 2003; 14(6):381-90. DOI: 10.1080/09537100310001598819. View

17.

Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K . Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. Thromb Res. 2001; 101(6):445-53. DOI: 10.1016/s0049-3848(00)00415-1. View

18.

Sun B, Le S, Lin S, Fong M, Guertin M, Liu Y . New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol. 2002; 40(4):577-85. DOI: 10.1097/00005344-200210000-00011. View

19.

Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J . Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2002; 19(4):369-86. DOI: 10.1111/j.1527-3466.2001.tb00076.x. View

20.

Cheepala S, Pitre A, Fukuda Y, Takenaka K, Zhang Y, Wang Y . The ABCC4 membrane transporter modulates platelet aggregation. Blood. 2015; 126(20):2307-19. PMC: 4643005. DOI: 10.1182/blood-2014-08-595942. View